Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy

Iori, Valentina, Iyer, Anand M., Ravizza, Teresa, Beltrame, Luca, Paracchini, Lara, Marchini, Sergio, Cerovic, Milica, Hill, Cameron, Ferrari, Mariella, Zucchetti, Massimo, Molteni, Monica, Rossetti, Carlo, Brambilla, Riccardo ORCID: https://orcid.org/0000-0003-3569-5706, White, H. Steve, D'Incalci, Maurizio, Aronica, Eleonora and Vezzani, Annamaria 2017. Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiology of Disease 99 , pp. 12-23. 10.1016/j.nbd.2016.12.007

[thumbnail of Iori et al 2016.pdf]
Preview
PDF - Accepted Post-Print Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (6MB) | Preview

Abstract

We recently discovered that forebrain activation of the IL-1 receptor/Toll-like receptor (IL-1R1/TLR4) innate immunity signal plays a pivotal role in neuronal hyperexcitability underlying seizures in rodents. Since this pathway is activated in neurons and glia in human epileptogenic foci, it represents a potential target for developing drugs interfering with the mechanisms of epileptogenesis that lead to spontaneous seizures. The lack of such drugs represents a major unmet clinical need. We tested therefore novel therapies inhibiting the IL-1R1/TLR4 signaling in an established murine model of acquired epilepsy. We used an epigenetic approach by injecting a synthetic mimic of micro(mi)RNA-146a that impairs IL1R1/TLR4 signal transduction, or we blocked receptor activation with antiinflammatory drugs. Both interventions when transiently applied to mice after epilepsy onset, prevented disease progression and dramatically reduced chronic seizure recurrence, while the anticonvulsant drug carbamazepine was ineffective. We conclude that IL-1R1/TLR4 is a novel potential therapeutic target for attaining disease-modifications in patients with diagnosed epilepsy.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Subjects: Q Science > Q Science (General)
Publisher: Elsevier
ISSN: 0969-9961
Date of First Compliant Deposit: 31 March 2017
Date of Acceptance: 7 December 2016
Last Modified: 06 Nov 2023 21:56
URI: https://orca.cardiff.ac.uk/id/eprint/98078

Citation Data

Cited 121 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics